- Market Capitalization, $K 5,874
- Shares Outstanding, K 2,012
- Annual Sales, $ 27,470 K
- Annual Income, $ -20,370 K
- 60-Month Beta 1.65
- Price/Sales 0.23
- Price/Cash Flow N/A
- Price/Book 1.17
|Period||Period Low||Period High||Performance|
| || |
-1.42 (-34.10%)since 10/14/19
| || |
-0.85 (-23.55%)since 08/14/19
| || |
-13.33 (-82.90%)since 11/14/18
Note Payment Received from Interpace Diagnostics Group, Inc.
Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it will effect a 1-for-30 reverse stock split of its outstanding...
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has closed on a $13 million Convertible Preferred Stock investment by Ampersand Capital Partners (Ampersand). This investment constitutes...
LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ --
Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced strategic, financial and operating results for the second quarter...
Sale of BioPharma business to Interpace Diagnostics Group, Inc.
Conference Call to be Held Tomorrow, Tuesday July 16, 2019 @ 8:30 am ET
Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and inflammatory diseases, today announced the appointment...
The conclusion of LabCorp's (LH) swap transaction will help enhance the company's Covance global nonclinical drug development capabilities with additional sites and resources.
The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.
Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.
The market is approaching oversold territory. Be watchful of a trend reversal.